These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26578622)

  • 1. Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
    Roelcke U; Wyss MT; Nowosielski M; Rudà R; Roth P; Hofer S; Galldiks N; Crippa F; Weller M; Soffietti R
    Neuro Oncol; 2016 May; 18(5):744-51. PubMed ID: 26578622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early metabolic responses in temozolomide treated low-grade glioma patients.
    Wyss M; Hofer S; Bruehlmeier M; Hefti M; Uhlmann C; Bärtschi E; Buettner UW; Roelcke U
    J Neurooncol; 2009 Oct; 95(1):87-93. PubMed ID: 19381442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.
    Galldiks N; Kracht LW; Burghaus L; Thomas A; Jacobs AH; Heiss WD; Herholz K
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):516-24. PubMed ID: 16450140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
    Harris RJ; Cloughesy TF; Pope WB; Nghiemphu PL; Lai A; Zaw T; Czernin J; Phelps ME; Chen W; Ellingson BM
    Neuro Oncol; 2012 Aug; 14(8):1079-89. PubMed ID: 22711609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas.
    Gempt J; Bette S; Ryang YM; Buchmann N; Peschke P; Pyka T; Wester HJ; Förster S; Meyer B; Ringel F
    Eur J Radiol; 2015 May; 84(5):955-62. PubMed ID: 25748815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Treatment Response Assessment Using
    Ceccon G; Lohmann P; Werner JM; Tscherpel C; Dunkl V; Stoffels G; Rosen J; Rapp M; Sabel M; Herrlinger U; Schäfer N; Shah NJ; Fink GR; Langen KJ; Galldiks N
    J Nucl Med; 2021 Jul; 62(7):918-925. PubMed ID: 33158907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
    Koekkoek JA; Dirven L; Heimans JJ; Postma TJ; Vos MJ; Reijneveld JC; Taphoorn MJ
    J Neurooncol; 2016 Jan; 126(2):347-54. PubMed ID: 26547911
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Suchorska B; Unterrainer M; Biczok A; Sosnova M; Forbrig R; Bartenstein P; Tonn JC; Albert NL; Kreth FW
    J Neurooncol; 2018 Sep; 139(3):721-730. PubMed ID: 29948765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling.
    Seligman L; Kovanlikaya I; Pisapia DJ; Naeger DM; Magge R; Fine HA; Chiang GC
    AJR Am J Roentgenol; 2019 Apr; 212(4):883-891. PubMed ID: 30779663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
    Pace A; Vidiri A; Galiè E; Carosi M; Telera S; Cianciulli AM; Canalini P; Giannarelli D; Jandolo B; Carapella CM
    Ann Oncol; 2003 Dec; 14(12):1722-6. PubMed ID: 14630675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
    Koekkoek JA; Dirven L; Heimans JJ; Postma TJ; Vos MJ; Reijneveld JC; Taphoorn MJ
    J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):366-73. PubMed ID: 25055819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
    Brada M; Viviers L; Abson C; Hines F; Britton J; Ashley S; Sardell S; Traish D; Gonsalves A; Wilkins P; Westbury C
    Ann Oncol; 2003 Dec; 14(12):1715-21. PubMed ID: 14630674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.
    Zinsz A; Ahrari S; Becker J; Mortada A; Roch V; Doriat L; Santi M; Blonski M; Taillandier L; Zaragori T; Verger A
    J Neurooncol; 2024 Sep; 169(2):241-245. PubMed ID: 38842696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of
    Debus C; Waltenberger M; Floca R; Afshar-Oromieh A; Bougatf N; Adeberg S; Heiland S; Bendszus M; Wick W; Rieken S; Haberkorn U; Debus J; Knoll M; Abdollahi A
    Sci Rep; 2018 May; 8(1):7201. PubMed ID: 29740097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
    Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
    Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET.
    Morana G; Piccardo A; Tortora D; Puntoni M; Severino M; Nozza P; Ravegnani M; Consales A; Mascelli S; Raso A; Cabria M; Verrico A; Milanaccio C; Rossi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2084-2093. PubMed ID: 28752225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.